health care, education and research updated cholesterol management guidelines donald brown, pharm.d,...

Health Care, Education and Research www.billingsclinic.com

Updated Cholesterol Management Guidelines

Donald Brown, Pharm.D, BCACP

May 3rd, 2014

Objectives

• Brief review of current and newer cholesterol lowering medications

• Discuss previous guidelines and how they compare to new guidelines

• Discuss controversy and treatment strategies

Pre-Lecture Questions

1. The updated cholesterol management guidelines address managing the statin intolerant patient.

– True or False

2. The updated cholesterol management guidelines risk calculator does not address patients less than 40 years old.

– True or False

3. Non-statin therapy has no place in managing patients’ cholesterol

– True or False

• The Art of James C. Christensen

Image available at: http://www.world-wide-art.com/images/James-Christensen/Low-Tech.jpg

Lipoprotein Metabolism

Image available at: http://pic.pimg.tw/mulicia/8a5d7405327f4b775ba83e725dff57f9.png

Cholesterol Lowering Medication

Statins



Cholesterol Absorption Inhibitor



Bile Acid Sequestrant



Niacin



Fibrates



Fish Oils


Current Arsenal

• Statins• Bile acid sequestrants• Ezetimibe• Fibrates • Niacin• Rx and OTC fish oil products• New

– Lomitapide (Juxtapib®) - MTTP inhibitor– Mypomersen (Kynamro®) – antisense

oligonucleotide

• Future? – PCSK9 inhibitors, CETP inhibitorsImage available at: http://www.3riversarchery.com/images/medium/6100X.jpg

Patient Case # 1

• 25 year old male with no medical history– No HTN, no DM, no smoking– Has a strong family history of premature CVD

• Father died of MI at age 42

– BMI = 25 kg/m^2– TC = 310 mg/dL– HDL-C = 50 mg/dL– TG = 400 mg/dL– LDL-C = 180 mg/dL

• Question: Should we start treatment?

Patient Case #2

• 64 year old male– No HTN, no DM, no smoking– SBP = 129 mmHg– TC = 180 mg/dL– HDL-C = 70 mg/dL– TG = 130 mg/dL– LDL-C = 84 mg/dL


SET THE WAY-BACK MACHINE

What Are We Used To?

• Adult Treatment Panel III Guidelines (2001)– Focused on:

• Primary prevention in patients with multiple risk factors

• Modifications of lipid classification

Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): executive summary. National Cholesterol Education Program Web site. Available at: http://www.nhlbi.nih.gov/guidelines/ cholesterol/atp3xsum.pdf.

Adult Treatment Panel III

• Patients with multiple risk factors– Patients with diabetes without CHD

• Raised to CHD risk level

– Used Framingham risk projections– Patient with the Metabolic Syndrome

• Candidates for intensified TLC



• Modified lipid classifications– LDL-C < 100 mg/dL --- optimal– Raised categorical HDL-C

• < 35 mg/dL to 40 mg/dL

– Lowered TG classifications• Gives more attention to moderate elevations


• Supported implementing– Complete lipoprotein profile – Use of plant stanols and soluble fiber – Importance of adherence to TLC and medication

therapies– Identified importance of treating patients with TG

>200 mg/dL (Non-HDL-C)



• Primary Target: LDL-C– Goal based on CV risk

• Secondary Target: Non-HDL-C– When LDL-C goal met and TG ≥ 200 mg/dL– Goal is always the LDL-C goal + 30



• Secondary Prevention in patients with established CVD– LDL-C goal:

• 100 mg/dL, further reduction to 70 mg/dL

– If LDL-C < 70 mg/dL is not achievable due to high baseline• LDL-C reduction of 50% with statins and/or combination

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): executive summary. National Cholesterol Education Program Web site. Available at: http://www.nhlbi.nih.gov/guidelines/ cholesterol/atp3xsum.pdf.

2. Smith SC, Jr, et al. J Am Coll Cardiol. 2006;47:2130-2139.

Framingham Risk

• Framingham risk score– 10 year risk of developing coronary heart disease– Takes into account patient’s:

• Age• Gender• Total cholesterol value• Smoking status• HDL-C value• SBP and treatment status


A Word About Risk

• Risk factors– Formation of plaques– Cause plaques to rupture

• Major Risk Factors:– Cigarette smoking– Hypertension– Low HDL-C– Diabetes

Back to Patient Case # 1

• 25 year old white male with no medical history– No HTN, no DM, no smoking– Has a strong family history of premature CVD



• Question: Should we start treatment?• ATP III: 1 risk factor, Fram risk ~ 1%

Back to Patient Case #2

• 64 year old white male– No HTN, no DM, no smoking– SBP = 129 mmHg– TC = 180 mg/dL– HDL-C = 70 mg/dL– TG = 130 mg/dL– LDL-C = 84 mg/dL

• Question: Should we start treatment?• ATP III: Age, HDL – risk factor, Fram Risk 5%

FAST FORWARD ABOUT 12-YEARS

Many Trials/Papers Published

HPS IDEAL AIM-HIGH PROVE-IT

ACCORD HPS-THRIVE ASCOT-LLA JUPITER

VA-HIT PROSPER METEOR CARDS

ALLHAT-LLT ARBITER-2 SEARCH TNT

SHARP ENHANCE IMPROVE-IT HOPE-3

ACC/AHA Guidelines 2013

• Non-statin therapies de-emphasized• Emphasized lifestyle as the foundation

to risk reduction

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Available at: http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a

What’s New?

1. Focus on ASCVD Risk Reduction: – 4 statin benefit groups

2. New perspective on LDL-C and/or Non-HDL-C treatment goals

3. Global risk assessment for primary prevention

4. Safety recommendations

5. Role of biomarkers and non-invasive tests


1. Four Statin Benefit Groups

• Four groups of primary and secondary prevention– Patients with clinical ASCVD– Patients with LDL-C ≥ 190 mg/dL– Patients with DM and no evidence of ASCVD

• 40 – 75 years old + LDL-C 70 – 189 mg/dL

– Patients w/o DM or ASCVD• LDL-C 70 – 189 mg/dL + 10-yrsk of ASCVD ≥ 7.5%


Origins of the Groups

• Randomized controlled trials– Who should get statin therapy and what intensity– Lowering of LDL-C 30 – 50% or more– Relative reduction in ASCVD risk consistent among

various patient groups

• Statin therapy reduces risk across spectrum of baseline LDL-C > 70 mg/dL


Defining Statin Intensity

• What are the statin intensity groups?– High intensity

• Lowers LDL-C ~ > 50%

– Moderate intensity• Lowers LDL-C ~ 30 to 50%

– Low intensity• Lowers LDL-C ~ < 30%

Rosuvastatin 20 – 40 mgAtorvastatin 40 – 80 mgAtorvastatin 10 – 20 mg

Rosuvastatin 5 – 10 mgSimvastatin 20 – 40 mgPravastatin 40 – 80 mgLovastatin 40 mgFluvastatin XL 80 mgFluvastatin 40mg BIDPitavastatin 2 – 4 mg

Simvastatin 10 mgPravastatin 10 – 20 mgLovastatin 20 mgFluvastatin 20 – 40 mgPitavastatin 1 mg

2. LDL “Goals” Perspective

• Paradigm shift– New perspective on treatment goals

• RCT evidence has only shown that ASCVD events are reduced by using the maximum tolerated statin dose

• The use of non-statin therapy– i.e. ezetimibe and niacin


LDL “Goals” Perspective

• Secondary prevention– Evidence only shows support for statin therapy to

maximally reduce LDL-C. • No support for a target

• FH w/ LDL-C > 190 mg/dL– May be difficult to achieve goal LDL-C < 100 despite

the use of 3 cholesterol-lowering medications• However, if patient achieves 50% reduction they are

receiving evidence based therapy


3. Global Risk Assessment

• Primary prevention– Use of a new pooled cohort equation– Identifying patients most likely to benefit– Who may not benefit

• Patient centered-approach– Risk reduction benefit, ADEs, DDIs and patient

preference


Risk Calculator

• Accounts for patient’s– Age, gender, ethnicity, SBP, …

Risk Calculator

Yes…There’s An App For That

4. Safety

• RCTs identified safety considerations– i.e Pre-diabetes

• Management of muscle symptoms• Use of pharmacists to aid in the safe use of

cholesterol lowering therapy

5. Biomarkers and Tests

• Role of biomarkers and non-invasive tests– Included recommendations to consider using

• LDL-C > 160 mg/dL• Evidence of genetic hyperlipidemias• Family history• hsCRP• CAC

CONTROVERSY

New Risk Calculator

• What was the equation/formula– Not yet provided– Not verified in prospective studies

• Of course, RCTs cannot available for every scenario – Should not mean a lack of evidence though

– Relies heavily on age and gender

More Patients on Statins

• 30 million more patients statin eligible• Younger than 40 years or older than 70

– May ignore treatment/prevention– May over treat primary prevention patient

• Lack of risk factors in calculator– Family history, CRP, Lp(a) or apoB

Raymond, C, Cho L, Rocco, M, Hazen SL. New Cholesterol Guidelines: Worth the Wait?. Cleveland Clinic Journal of Medicine.81(1).Jan 2014:11-19.O’Riordan M. New Cholesterol Guidelines Abandon LDL Targets. Available at: http://www.medscape.com/viewarticle/814152#1

Scatter plot with best-fit lines of major lipid trials (statin and nonstatin trials) for both primary and secondary prevention of coronary heart disease events.

RAYMOND C et al. Cleveland Clinic Journal of Medicine 2014;81:11-19

©2014 by Cleveland Clinic

Statin-intolerant Patients

• Recommend determine causal relationship with statin

• Investigate other possible causes• Stopping and re-starting statin therapy• Switch to another statin at a lower dose

• Truly intolerant statin?

Quality Measures

• What could this mean for quality measures– No targets, but insurance companies

• Is lack of LDL-C goals a flaw?• Necessary to repeat lipid levels?


Other Contentious Points

• No period for open comment/critique• Apparent lack of attempt to correlate with other

guidelines


Back to Patient Case # 1

• 25 year old male with no medical history– No HTN, no DM, no smoking– Has a strong family history of premature CVD




• According to new calculator– Risk calculator does not apply to him

• Less than 40 years old

– Even at 40 his 10-year risk is 3.1%– “Eligible” for statin therapy at 58 years– Comfortable waiting to start therapy?

• Of course you wouldn’t base decision solely on a risk calculator– If difficulty identifying patient for a statin group could

use other risks• History of premature atherosclerotic cardiovascular disease

in first degree relative• High sensitivity-reactive protein (CRP) > 2 mg/L• Coronary Artery Calcium (CAC) scan

Back to Patient Case #2

• 64 year old male– No HTN, no DM, no smoking– SBP = 129 mmHg– TC = 180 mg/dL– HDL-C = 70 mg/dL– TG = 130 mg/dL– LDL-C = 84 mg/dL

• Calculated risk = 7.5%

Patient Case #3

• 64 year old male– 2 pack per day smoker– Untreated HTN (SBP = 150 mmHg)– TC = 153 mg/dL– HDL-C = 70 mg/dL– TG = 60 mg/dL– LDL-C = 71 mg/dL

• Calculated risk = 10.5%

Summary

• There is controversy, but…• Should be treating diabetics more aggressively • TLC remains a cornerstone

Post-Lecture Questions

1. The updated cholesterol management guidelines address managing the statin intolerant patient.

– True or False

2. The updated cholesterol management guidelines risk calculator does not address patients less than 40 years old.

– True or False

3. Non-statin therapy has no place in managing patients’ cholesterol

– True or False

QUESTIONS/COMMENTS

health care, education and research updated cholesterol management guidelines donald brown, pharm.d,...

Documents

false slide

atherogenesis slide

machine slide

treatment strategies

newer cholesterol

patients cholesterol

christensen image available

mgdl tg